Home » Stocks » AKTX

Akari Therapeutics, PLC (AKTX)

Stock Price: $3.51 USD 0.05 (1.45%)
Updated Feb 25, 2021 1:47 PM EST - Market open
Market Cap 135.04M
Revenue (ttm) n/a
Net Income (ttm) -17.11M
Shares Out 1.83B
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $3.51
Previous Close $3.46
Change ($) 0.05
Change (%) 1.45%
Day's Open 3.54
Day's Range 3.27 - 3.60
Day's Volume 197,247
52-Week Range 0.87 - 4.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 hours ago

NEW YORK and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimm...

GlobeNewsWire - 3 weeks ago

NEW YORK and LONDON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimm...

GlobeNewsWire - 1 month ago

NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimm...

GlobeNewsWire - 2 months ago

NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimm...

GlobeNewsWire - 2 months ago

NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimm...

GlobeNewsWire - 2 months ago

NEW YORK and LONDON, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inf...

GlobeNewsWire - 3 months ago

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inf...

GlobeNewsWire - 4 months ago

NEW YORK and LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inf...

GlobeNewsWire - 4 months ago

NEW YORK and LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inf...

GlobeNewsWire - 4 months ago

NEW YORK and LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan auto...

GlobeNewsWire - 5 months ago

NEW YORK and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan auto...

GlobeNewsWire - 5 months ago

NEW YORK and LONDON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a Phase III biopharmaceutical company focused on innovative therapeutics to treat orphan autoi...

GlobeNewsWire - 6 months ago

NEW YORK and LONDON, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

GlobeNewsWire - 7 months ago

NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercial...

GlobeNewsWire - 7 months ago

NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercial...

GlobeNewsWire - 8 months ago

NEW YORK and LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

GlobeNewsWire - 9 months ago

NEW YORK and LONDON, May 21, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

GlobeNewsWire - 9 months ago

NEW YORK and LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

GlobeNewsWire - 11 months ago

NEW YORK and LONDON, March 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and ...

GlobeNewsWire - 1 year ago

NEW YORK and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

GlobeNewsWire - 1 year ago

NEW YORK and LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat autoimmune and inflamma...

GlobeNewsWire - 1 year ago

All patients treated with nomacopan have achieved the primary endpoint of transfusion independence All patients treated with nomacopan have achieved the primary endpoint of transfusion indepen...

GlobeNewsWire - 1 year ago

NEW YORK and LONDON, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

GlobeNewsWire - 1 year ago

NEW YORK and LONDON, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

GlobeNewsWire - 1 year ago

NEW YORK and LONDON, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

GlobeNewsWire - 1 year ago

NEW YORK and LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and ...

Zacks Investment Research - 1 year ago

The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

GlobeNewsWire - 1 year ago

NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and ...

GlobeNewsWire - 1 year ago

NEW YORK and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and ...

Zacks Investment Research - 1 year ago

The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.

Benzinga - 1 year ago

Akari Therapeutics PLC (NASDAQ: AKTX) shares are on track to reclaim the $2 level for the first time since mid-August thanks to two doses of positive tidings from the company.

Market Watch - 1 year ago

Akari Therapeutics PLC shares AKTX, +12.21% soared 13% in premarket trade Friday, after the company said it has won U.S.

GlobeNewsWire - 1 year ago

NEW YORK and LONDON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

GlobeNewsWire - 1 year ago

- Positive early safety and efficacy data with nomacopan

InvestorPlace - 1 year ago

Some recent biopharma news concerning Akari Therapeutics getting Fast Track approval from the FDA has AKTX stock flying high on Wednesday. The post Biopharma News: Why Akari Therapeutics (AKT...

Benzinga - 1 year ago

The thinly traded, nano-cap biotech Akari Therapeutics PLC (NASDAQ: AKTX) gap-opened higher Wednesday morning, and shares were advancing strongly on above-average volume.

24/7 Wall Street - 1 year ago

Akari Therapeutics PLC (NASDAQ: AKTX) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its stem cell ...

Market Watch - 1 year ago

Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its treatment (nomacopan) of stem-cell tr...

Zacks Investment Research - 1 year ago

Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

Benzinga - 1 year ago

Shares of Akari Therapeutics PLC (NASDAQ: AKTX)  were soaring Wednesday.

Seeking Alpha - 1 year ago

Akari announced positive results from its phase 2 study using Coversin to treat patients with bullous pemphigoid.

Benzinga - 1 year ago

Akari Therapeutics PLC (NASDAQ: AKTX) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month.

Benzinga - 1 year ago

Akari Therapeutics PLC shares were surging by more than 150 percent Wednesday after reporting a positive meeting with the FDA.

Market Watch - 1 year ago

Shares of Akari Therapeutics PLC more than doubled--soaring 145%--toward a 15-month high in very active morning trade Wednesday.

About AKTX

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdo... [Read more...]

Industry
Biotechnology
CEO
David Solomon
Employees
10
Stock Exchange
NASDAQ
Ticker Symbol
AKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for AKTX stock is "Strong Buy" and the 12-month stock price forecast is 5.00.

Price Target
$5.00
Analyst Consensus: Strong Buy